520 related articles for article (PubMed ID: 28324751)
1. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.
Brochez L; Chevolet I; Kruse V
Eur J Cancer; 2017 May; 76():167-182. PubMed ID: 28324751
[TBL] [Abstract][Full Text] [Related]
2. Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy.
Yentz S; Smith D
BioDrugs; 2018 Aug; 32(4):311-317. PubMed ID: 29980987
[TBL] [Abstract][Full Text] [Related]
3. Marrying immunotherapy with chemotherapy: why say IDO?
Muller AJ; Prendergast GC
Cancer Res; 2005 Sep; 65(18):8065-8. PubMed ID: 16166276
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.
Katz JB; Muller AJ; Prendergast GC
Immunol Rev; 2008 Apr; 222():206-21. PubMed ID: 18364004
[TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.
Muller AJ; Malachowski WP; Prendergast GC
Expert Opin Ther Targets; 2005 Aug; 9(4):831-49. PubMed ID: 16083346
[TBL] [Abstract][Full Text] [Related]
6. Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence.
Ricciuti B; Leonardi GC; Puccetti P; Fallarino F; Bianconi V; Sahebkar A; Baglivo S; Chiari R; Pirro M
Pharmacol Ther; 2019 Apr; 196():105-116. PubMed ID: 30521884
[TBL] [Abstract][Full Text] [Related]
7. Companies Scaling Back IDO1 Inhibitor Trials.
Cancer Discov; 2018 Jul; 8(7):OF5. PubMed ID: 29848606
[TBL] [Abstract][Full Text] [Related]
8. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.
Selvan SR; Dowling JP; Kelly WK; Lin J
Curr Cancer Drug Targets; 2016; 16(9):755-764. PubMed ID: 26517538
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.
Munn DH
Curr Opin Immunol; 2006 Apr; 18(2):220-5. PubMed ID: 16460921
[TBL] [Abstract][Full Text] [Related]
10. Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.
Johnson TS; Munn DH
Immunol Invest; 2012; 41(6-7):765-97. PubMed ID: 23017145
[TBL] [Abstract][Full Text] [Related]
11. Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects.
Jiang X; Li X; Zheng S; Du G; Ma J; Zhang L; Wang H; Tian J
Int J Immunopathol Pharmacol; 2020; 34():2058738420950584. PubMed ID: 32962460
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
13. The inhibition of indoleamine 2, 3-dioxygenase 1 by connexin 43.
Lin HC; Yang CJ; Kuan YD; Wang WK; Chang WW; Lee CH
Int J Med Sci; 2017; 14(12):1181-1188. PubMed ID: 29104473
[TBL] [Abstract][Full Text] [Related]
14. The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma.
Jia H; Ren W; Feng Y; Wei T; Guo M; Guo J; Zhao J; Song X; Wang M; Zhao T; Wang H; Feng Z; Tian Z
Int J Oncol; 2018 Sep; 53(3):949-960. PubMed ID: 30015838
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3-dioxygenase: is it an immune suppressor?
Soliman H; Mediavilla-Varela M; Antonia S
Cancer J; 2010; 16(4):354-9. PubMed ID: 20693847
[TBL] [Abstract][Full Text] [Related]
16. Research progress of indoleamine 2,3-dioxygenase inhibitors.
Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
Liu X; Shin N; Koblish HK; Yang G; Wang Q; Wang K; Leffet L; Hansbury MJ; Thomas B; Rupar M; Waeltz P; Bowman KJ; Polam P; Sparks RB; Yue EW; Li Y; Wynn R; Fridman JS; Burn TC; Combs AP; Newton RC; Scherle PA
Blood; 2010 Apr; 115(17):3520-30. PubMed ID: 20197554
[TBL] [Abstract][Full Text] [Related]
18. Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development.
Zhu MMT; Dancsok AR; Nielsen TO
Curr Oncol Rep; 2019 Jan; 21(1):2. PubMed ID: 30659394
[TBL] [Abstract][Full Text] [Related]
19. Indoleamine 2,3 dioxygenase and human leucocyte antigen-G inhibit the T-cell alloproliferative response through two independent pathways.
Le Rond S; Gonzalez A; Gonzalez AS; Carosella ED; Rouas-Freiss N
Immunology; 2005 Nov; 116(3):297-307. PubMed ID: 16236119
[TBL] [Abstract][Full Text] [Related]
20. Influence of tryptophan contained in 1-Methyl-Tryptophan on antimicrobial and immunoregulatory functions of indoleamine 2,3-dioxygenase.
Schmidt SK; Siepmann S; Kuhlmann K; Meyer HE; Metzger S; Pudelko S; Leineweber M; Däubener W
PLoS One; 2012; 7(9):e44797. PubMed ID: 23028625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
